Suh D S, Zhou Y, Ooi G T, Rechler M M
Growth and Development Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
Mol Endocrinol. 1996 Oct;10(10):1227-37. doi: 10.1210/mend.10.10.9121490.
Insulin-like growth factor binding protein-1 (IGFBP-1) modulates the mitogenic actions of IGF-I and IGF-II. Dexamethasone increases IGFBP-1 mRNA abundance and gene transcription in rat liver and in H4-II-E rat hepatoma cells. A glucocorticoid response element (GRE) located at nucleotide (nt) -91/-77 is required for dexamethasone to stimulate rat IGFBP-1 promoter activity in transient transfection assays in H4-II-E cells. Mutagenesis of nt -108/-99 (the M4 region of the insulin response element), however, decreased dexamethasone-stimulated promoter activity despite the presence of an intact GRE, suggesting that regulatory sites in addition to the GRE were required for optimal dexamethasone stimulation. To identify these sites, we introduced 5'-deletion and substitution mutations into rat IGFBP-1 promoter fragments coupled to a luciferase reporter gene and transfected these constructs into H4-II-E cells. Three sites are required for optimal basal promoter activity: a site (nt -62/-50) that binds the liver-enriched transcription factor, hepatocyte nuclear factor-1 (HNF-1), the M4 site, and a putative binding site for transcription factor AP-2 (nt -293/-286). The HNF-1 and M4 sites and an upstream site (nt -252/-236) are also involved in dexamethasone stimulation under some, but not all, circumstances. Mutation of either the HNF-1 site or the M4 site decreased dexamethasone stimulation by more than 80% in constructs whose 5'-end was at nt -92, -135, or -235 but not if the 5' -end was at nt -278 or -327. These results suggest that the nt -278/-236 region can compensate for the loss of the HNF-1 site or the M4 site but that the HNF-1 and M4 sites do not compensate for each other in constructs whose 5'-end was at nt -135 or -235, which lack the nt -278/-236 region. The site within the nt -278/-236 region was localized to nt -252/-236 by deoxyribonuclease I protection and transfection assays. Thus, several cis-elements in the rat IGFBP-1 promoter cooperate, in varying combinations, with the low-affinity GRE to allow optimal dexamethasone-stimulated promoter activity.
胰岛素样生长因子结合蛋白-1(IGFBP-1)调节IGF-I和IGF-II的促有丝分裂作用。地塞米松可增加大鼠肝脏和H4-II-E大鼠肝癌细胞中IGFBP-1 mRNA丰度和基因转录。在H4-II-E细胞的瞬时转染实验中,位于核苷酸(nt)-91 / -77处的糖皮质激素反应元件(GRE)是地塞米松刺激大鼠IGFBP-1启动子活性所必需的。然而,nt -108 / -99(胰岛素反应元件的M4区域)的诱变降低了地塞米松刺激的启动子活性,尽管存在完整的GRE,这表明除了GRE之外还需要其他调控位点才能实现最佳的地塞米松刺激。为了鉴定这些位点,我们将5'-缺失和取代突变引入与荧光素酶报告基因偶联的大鼠IGFBP-1启动子片段中,并将这些构建体转染到H4-II-E细胞中。最佳基础启动子活性需要三个位点:一个与肝脏富集转录因子肝细胞核因子-1(HNF-1)结合的位点(nt -62 / -50)、M4位点和转录因子AP-2的假定结合位点(nt -293 / -286)。在某些但不是所有情况下,HNF-1和M4位点以及一个上游位点(nt -252 / -236)也参与地塞米松刺激。在5'-末端位于nt -92、-135或-235的构建体中,HNF-1位点或M4位点的突变使地塞米松刺激降低超过80%,但如果5'-末端位于nt -278或-327则不会。这些结果表明,nt -278 / -236区域可以补偿HNF-1位点或M4位点的缺失,但在5'-末端位于nt -135或-235且缺乏nt -278 / -236区域的构建体中,HNF-1和M4位点不能相互补偿。通过脱氧核糖核酸酶I保护和转染实验,nt -278 / -236区域内的位点定位于nt -252 / -236。因此,大鼠IGFBP-1启动子中的几个顺式元件以不同组合与低亲和力GRE协同作用,以实现最佳的地塞米松刺激启动子活性。